AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01942161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole High (24 - 30 mg/day)
Description: administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
Study NCT00072930 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-522
Description: IV at a concentration of 50 mg/mL and 10mL vials
Study NCT00072930 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Docetaxel + Prednisone* + Zoledronic Acid
Description: IV 75 mg/m2 IV 3-4 mg 5 mg
Study NCT02555813 — intervention group
Intervention type: DRUG
Intervention: Abraxane
Description: Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity
Study NCT02555813 — intervention group
Intervention type: DRUG
Intervention: Gemcitabine
Description: Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity
Study NCT02186379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RePace Intervention
Description: The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
Study NCT02186379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters.
Study NCT04036474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking Prevention Education Program
Description: The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness.
Study NCT00760435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 5 mg/kg IV over 2 hours once
Study NCT00760435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (same volume as active drug)
Study NCT04245670 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5
Description: Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
Study NCT02969291 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reduced Sedentary Time Intervention (RSTI)
Description: Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
Study NCT01023555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1cc of blood in a single aerobic culture bottle
Description: The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
Study NCT04245267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIABEMPIC
Description: Patients are attended by 9 diabetes health-care professionals every 2 weeks for 5 months in a shared medical appointment scheme, including individual and group sessions. Patients will be evaluated at the end of the program and 1 year after.
Study NCT01289353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV, weekly for 6 weeks, AUC of 2.0
Study NCT01289353 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-RT or IMRT
Description: From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy
Study NCT00538967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 2 weeks once daily
Study NCT00071513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAST-T/HSTS
Description: Skills training small group.
Study NCT00071513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention
Description: Assessment of needs and referral to services as needed.
Study NCT03274505 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: * Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~* Clinical evaluation~* Routine neuropsychological evaluation (for stroke patients)~* Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) > 10)
Study NCT00439660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Rotavirus Vaccine 116E Live Attenuated
Study NCT00349804 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cool dry air
Description: cool dry air (0.22-0.28 m3/min at 15-18 Degrees C)
Study NCT02365090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patching
Description: covering the sound eye with a patch to force use of the amblyopic eye
Study NCT02365090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: binocular games
Description: playing iPad games 1 hour per day 5 days per week to allow the child to use the amblyopic eye and the sound eye together
Study NCT01214629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).
Study NCT01214629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.
Study NCT01214629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 milligrams (mg) administered subcutaneously on Day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
Study NCT00138203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO
Study NCT00138203 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01958008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 high dose b.i.d.
Description: Film-coated tablet
Study NCT01958008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 low dose b.i.d.
Description: Film-coated tablet
Study NCT01958008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 high dose b.i.d.
Description: Film-coated tablet
Study NCT01958008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 medium dose b.i.d.
Description: Film-coated tablet
Study NCT01958008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 low dose b.i.d.
Description: Film-coated tablet
Study NCT01958008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 medium dose b.i.d.
Description: Film-coated tablet
Study NCT03020199 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab (AIN457) 300 mg was administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose was provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe was labeled as AIN457 150 mg/1 mL.
Study NCT03020199 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: nb-UVB
Description: Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application was performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face was recommended
Study NCT03674996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same day discharge
Description: Discharge of the patient 12 hours after the minimally invasive radical prostatectomy - experimental group
Study NCT04940559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - Softgel
Description: Oral softgel capsule.
Study NCT04940559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - LFC
Description: Oral LFC.
Study NCT03674996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Next-day discharge
Description: Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - experimental group
Study NCT03674996 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 2-days discharge
Description: Discharge of the patient 24 hours after the minimally invasive radical prostatectomy - control group
Study NCT03341949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recurring blood sample
Description: An additional tube will be collected for the assay of CD146s as part of the research
Study NCT01161147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam Tablets 15 mg
Study NCT01161147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam
Description: Meloxicam Tablets 15 mg
Study NCT01776333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: video decision aid
Study NCT00679302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Description: Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
Study NCT05234632 — intervention group
Intervention type: DEVICE
Intervention: PICO 14 single-use Negative Pressure Wound Therapy System
Description: The PICO14 device delivers negative pressure across the wound bed or closed incision and surrounding area, and exudate is managed by the dressing through a combination of absorption and evaporation of moisture through the outer film.
Study NCT00248287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan + Carboplatin
Description: irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
Study NCT00248287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan + Carboplatin + erbitux
Description: irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
Study NCT03967977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: 200 mg administered Intravenously (IV) as specified in the treatment arm
Study NCT03967977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tislelizumab placebo to match
Study NCT03967977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 70 mg/m2 administered IV as specified in the treatment arm
Study NCT03967977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 70 mg/m2 administered IV as specified in the treatment arm
Study NCT03967977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: 1000 mg/m2 administered IV as specified in the treatment arm
Study NCT03967977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: 1000 mg/m2 administered IV as specified in the treatment arm
Study NCT03967977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
Study NCT00679302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
Study NCT03967977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area Under the Curve (AUC) 4.5 administered IV as specified in the treatment arm
Study NCT04277858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Subjects will be treated with neoadjuvant docetaxel and cisplatin for 3 cycles. This is followed by transoral robotic surgery (TORS) and neck dissection as definitive treatment, reserving radiotherapy for salvage.
Study NCT01050426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UFT, Leucovorin
Description: UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)
Study NCT01050426 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: UFT/ Leucovorin + Cetuximab + Radiotherapy
Description: UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
Study NCT01691001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.
Study NCT01691001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study NCT01126476 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proton Radiotherapy
Study NCT03096795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3506
Description: Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 or Dose 2 or Dose 3 or Dose 4 or Dose 5 or Dose 6 subcutaneously and Dose 6 intravenously in Part 1. Participants with COPD will receive 3 administration of MEDI3506 Dose 4 or Dose 5 or Dose 6 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of MEDI3506 Dose 6 intravenously in Part 3.
Study NCT03096795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MEDI3506
Description: Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single MEDI3506 Dose 1 or Dose 2 or Dose 3 or Dose 4 or Dose 5 or Dose 6 subcutaneously and Dose 6 intravenously in Part 1. Participants with COPD will receive 3 administration of MEDI3506 Dose 4 or Dose 5 or Dose 6 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of MEDI3506 Dose 6 intravenously in Part 3.
Study NCT03096795 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy participants with a history of mild atopy and proven sensitivity to HDM will receive a single dose of placebo matched to MEDI3506 subcutaneously or intravenously in Part 1. Participants with COPD will receive 3 administration of placebo matched to MEDI3506 subcutaneously two weeks apart over a 4-week dosing period in Part 2. Healthy Japanese participants will receive a single dose of placebo matched to MEDI3506 intravenously in Part 3.
Study NCT00417378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device Impella LP 2.5
Description: Left Ventricular Assist Device
Study NCT00417378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraaortic Balloon Pump
Description: Counterpulsation
Study NCT03257202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 1% Gel
Description: topical clindamycin
Study NCT03257202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide 5% gel
Description: topical benzoyl peroxide
Study NCT03257202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BenzaClin 5%-1% Topical Gel
Description: Topical clindamycin and benzoyl peroxide together
Study NCT00562497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochymal®
Description: Prochymal® intravenous infusion.
Study NCT00562497 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching Prochymal® intravenous infusion.
Study NCT00562497 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: Administration will be intravenously as prescribed by the caregiver.
Study NCT00562497 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Administration will be intravenously as prescribed by the caregiver.
Study NCT00633074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)
Description: Intramuscular administration, 1 dose
Study NCT00633074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)
Description: Intramuscular administration, 1 dose
Study NCT00365105 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
Study NCT02115724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail
Description: Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
Study NCT02115724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biopsy
Description: Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
Study NCT02115724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
Study NCT02115724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMD; 0.4mg sub-lingual nitroglycerin spray
Description: Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
Study NCT06076512 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral therapy
Description: Behavioral and supportive therapy
Study NCT03697096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Routine Antibiotic Stewardship Arm - Continuation of all antibiotic stewardship activities in accordance with national standards.
Study NCT03697096 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: INSPIRE CPOE Smart Prompt
Description: Quality improvement intervention: computerized physician order entry (CPOE) decision support alert that provides physicians with patient-specific risk estimate of having a UTI due to a multidrug resistant organism (MDRO) and recommends appropriate antibiotic choice for non-ICU patients in the first 3 days of hospitalization.~Continuation of other antibiotic stewardship activities in accordance with national standards.
Study NCT03263650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 25mg/m2 administered intravenously over 60 minutes on day 1 of cycles 1-6; given before carboplatin.
Study NCT03263650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 4 administered intravenously over 60 minutes on day 1 of cycles 1-6